Table 1. Baseline clinical characteristics, exacerbations and hospitalizations before and after treatment with roflumilast.
| Variable | Values |
|---|---|
| Age (years), mean ± SD | 66.2±9.3 |
| Male, n (%) | 73 (88.0) |
| BMI (kg/m2), mean ± SD | 25.6±5.1 |
| FEV1 (%), mean ± SD | 33.9±10.7 |
| FEV1 (L), mean ± SD | 0.96±0.31 |
| FEV1/FVC (%), mean ± SD | 56.4±13.7 |
| Smoke load (packs/years), mean ± SD | 44.5±31.8 |
| Smoking status, n (%) | |
| Current | 14 (16.9) |
| Former | 61 (73.5) |
| Duration of roflumilast use (month), mean ± SD | 18.9 ±10.4 |
| Exacerbation rates before to and after roflumilast (event/year), mean ± SD | 2.7±1.68 vs. 1.16±1.36* |
| Hospitalization rates due to respiratory causes before to and after roflumilast (event/year), mean ± SD | 0.77±0.92 vs. 0.32±0.73* |
*, P<0.001.